Literature DB >> 7543232

Platelet-derived growth factor receptor immunoreactivity in mesothelioma and nonneoplastic mesothelial cells in serous effusions.

V Ascoli1, C C Scalzo, F Facciolo, F Nardi.   

Abstract

Expression of the platelet-derived growth factor receptor (PDGFR) was detected by immunocytochemistry in normal and malignant mesothelial cells from 14 benign effusions and 22 mesotheliomas. Two well-characterized antireceptor monoclonal antibodies to the PDGFR alpha-subunit (PR292) and beta-subunit (PR7212) were used. PDGFR alpha-subunit outlined cell membranes intensely in nonneoplastic mesothelial cells, whereas it was focal in mesothelioma and limited to a few cases only. PDGFR beta-subunit was weakly expressed in the cytoplasm of normal mesothelium; in contrast, malignant mesothelial cells showed strong cytoplasmic staining. Our results show that normal mesothelium may be responsive to PDGF by the predominant expression of PDGFR-alpha and less by PDGFR-beta and indicate the presence of growth-stimulation loops in mesothelioma through PDGF/PDGFR-beta interaction. Also, scattered staining for the PDGFR alpha-subunit suggests that a PDGF-A chain/PDGFR-alpha interaction may also be active in mesothelioma cells growing in suspension.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543232

Source DB:  PubMed          Journal:  Acta Cytol        ISSN: 0001-5547            Impact factor:   2.319


  4 in total

1.  An unusual complex karyotype in myopericytoma.

Authors:  Aaron W James; Le Chang; Swati Shrestha; Carlos A Tirado; Sarah M Dry
Journal:  J Orthop       Date:  2015-01-29

2.  Elevated PDGFRB gene copy number gain is prognostic for improved survival outcomes in resected malignant pleural mesothelioma.

Authors:  Anne S Tsao; Nusrat Harun; Junya Fujimoto; Vikki Devito; J Jack Lee; Elisabetta Kuhn; Reza Mehran; David Rice; Cesar Moran; Waun Ki Hong; Li Shen; Milind Suraokar; Ignacio Wistuba
Journal:  Ann Diagn Pathol       Date:  2014-02-20       Impact factor: 2.090

3.  Phase I trial of cisplatin, pemetrexed, and imatinib mesylate in chemonaive patients with unresectable malignant pleural mesothelioma.

Authors:  Anne S Tsao; Nusrat Harun; J Jack Lee; John Heymach; Katherine Pisters; Waun Ki Hong; Junya Fujimoto; Ignacio Wistuba
Journal:  Clin Lung Cancer       Date:  2013-12-27       Impact factor: 4.785

4.  Expression of cancer-associated molecules in malignant mesothelioma.

Authors:  Ben Davidson
Journal:  Biomark Insights       Date:  2007-05-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.